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Abstract 
TGF-β1 has been long considered as a key mediator in renal fibrosis and induces renal scarring 
largely by activating its downstream Smad signaling pathway. Interestingly, while mice over-
expressing active TGF-β1 develop progressive renal injury, latent TGF-β1 plays a protective 
role in renal fibrosis and inflammation. Under disease conditions, Smad2 and Smad3 are highly 
activated, while Smad7 is degraded through the ubiquitin proteasome degradation mechanism. 
In addition to TGF-β1, many pathogenic mediators such as angiotensin II and advanced gly-
cation end products can also activate the Smad pathway via both TGF-β-dependent and in-
dependent mechanisms. Smads interact with other signaling pathways, such as the MAPK and 
NF-κB pathways, to positively or negatively regulate renal inflammation and fibrosis. Studies 
from gene knockout mice demonstrate that TGF-β1 acts by stimulating its downstream 
Smads to diversely regulate kidney injury. In the context of renal fibrosis and inflammation, 
Smad3 is pathogenic, while Smad2 and Smad7 are protective. Smad4 exerts its diverse roles by 
transcriptionally enhancing Smad3-mediated renal fibrosis while inhibiting NF-κB-driven renal 
inflammation via a Smad7-dependent mechanism. Furthermore, we also demonstrated that 
TGF-β1 acts by stimulating Smad3 to positively or negatively regulate microRNAs to exert its 
fibrotic role in kidney disease. In conclusion, TGF-β/Smad signaling is a major pathway leading 
to kidney disease. Smad3 is a key mediator in renal fibrosis and inflammation, whereas Smad2 
and Smad7 are renoprotective. Smad4 exerts its diverse role in promoting renal fibrosis while 
inhibiting inflammation. Thus, targeting the downstream TGF-β/Smad3 signaling pathway by 
gene transfer of either Smad7 or Smad3-dependent microRNAs may represent a specific and 
effective therapeutic strategy for kidney disease. 
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Introduction 
Renal fibrosis characterized by accumulation of 
fibroblasts and excessive matrix proteins along with a 
loss of functioning nephrons are a major pathological 
feature of progressive kidney disease [1]. Many stud-
ies have shown that progressive renal fibrosis is me-
diated by multiple mediators including growth fac-
tors, cytokines, metabolic toxins, and stress molecules 
via multiple mechanisms and pathways.  Among 
them, transforming growth factor-β1  (TGF-β1) has 
been recognized as a key mediator in the pathogenesis 
of renal fibrosis [1-3].  
TGF-β is a founding member of the TGF-β su-
perfamily including activins, inhibins, growth and 
differentiation factors, and bone morphogenetic pro-
teins. TGF-β1 and its isoforms (TGF-β2 and TGF-β3) 
are synthesized by a variety of cells including all cell 
types of the kidney and secreted as latent precursors 
(latent TGF-β1) complexed with latent TGF-β binding 
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proteins (LTBP) [3, 4]. TGF-β1 becomes active when 
TGF-β1 is liberated from the latency-associated pep-
tide (LAP) and dissociated from LTBP via proteolytic 
cleavage by plasmin, reactive oxygen species, 
thrombospondin-1, and acid [3, 4]. Active TGF-β then 
binds its receptors and functions as autocrine and 
paracrine manners to exert its biological and patho-
logical activities via Smad-dependent and independ-
ent  signaling pathways [5].  Of them, the 
Smad-dependent mechanism has been well studied 
and considered to be a major pathway in many 
pathophysiological processes of kidney disease [2, 3, 
6].  
It is now well established that the binding of 
TGF-β1 to its receptor II (TβRII) can activate the 
TGF-β  receptor type I (TβRI)-kinase, resulting in 
phosphorylation of Smad2 and Smad3, two recep-
tor-associated Smads (R-Smads).  Subsequently, 
phosphorylated Smad2 and Smad3 bind to the com-
mon Smad4  and  form the Smad complex, which 
translocates into the  nucleus  to  regulate the target 
gene transcription, including Smad7 (Figure 1). 
Smad7 is an inhibitory Smad that negatively regulates 
Smad2 and Smad3 activation and functions by tar-
geting the TβRI and Smads for degradation via the 
ubiquitin proteasome degradation mechanisms [7, 8].  
In this review, the major task is to focus on the 
molecular mechanisms of TGF-β/Smads in diversely 
regulating renal fibrosis and inflammation during 
progressive kidney injury. In addition, the new 
therapeutic approaches for kidney disease by 
targeting the downstream TGF-β/Smad signal-
ing with gene transfer of Smad7 and 
TGF-β/Smad3-dependent microRNAs are also 
described.  
 
Figure 1. TGF-β/Smads and crosstalk pathways 
in renal fibrosis and inflammation. After binding 
to TβRII, TGF-β1 activates the TβRI-kinase  which 
phosphorylates Smad2 and Smad3.  The  phosphory-
lated Smad2 and Smad3 then bind to Smad4 and form 
the Smad complex, which translocates into the nucleus 
and regulates the target gene transcription, including 
Smad7. Smad7 is an inhibitory Smad that functions to 
block Smad2/3 activation by degrading the TβRI and 
Smads and to inhibit NF-κB-driven inflammatory re-
sponse by inducing IκBα, an inhibitor of NF-κB. Note 
that Ang II and AGEs can activate Smads independent 
of TGF-β1 via the ERK/p38/MAPK crosstalk pathway. 
Blue lines (symbols) indicate protective or negative 
regulation pathways, while red arrows (symbols) 
represent pathogenic or positive regulation pathways.  
TGF-β1 is a key mediator in kidney disease 
Increasing evidence shows that TGF-β1 is a key 
mediator in the pathogenesis of renal fibrosis in both 
experimental and human kidney diseases because 
TGF-β1 is highly upregulated in the diseased kidney 
with severe renal fibrosis [2, 3]. TGF-β1 mediates 
progressive renal fibrosis by stimulating extracellular 
matrix (ECM) production while inhibiting its degra-
dation. In addition, TGF-β1 also mediates renal fibro-
sis by inducing the transformation of tubular epithe-
lial cells (TECs) to myofibroblasts through epitheli-
al-mesenchymal transition (EMT) [9]. The functional 
role of TGF-β1in EMT and renal fibrosis is demon-
strated by the ability of blocking TGF-β1 with neu-
tralizing TGF-β  antibodies, decorin, and antisense 
oligonucleotides to prevent or ameliorate renal fibro-
sis in vivo and in vitro [10]. Direct evidence for a role 
of TGF-β1 in renal fibrosis comes from studies that 
mice overexpressing an active form of TGF-β1 in liver 
develop progressive liver and renal fibrosis [11, 12].  
While the critical role of TGF-β1 in renal fibrosis 
has been well recognized, little  attention has been 
paid to the role of TGF-β1 in renal inflammation. 
TGF-β1 is also known as an anti-inflammation cyto-
kines [13].  Mice deficient for TGF-β1 results in the 
development of a lethal inflammation and death at 3 
weeks of age [14]. Similarly, conditional deletion of 
TβRII or TGF-β1 gene from T cells develops autoim-Int. J. Biol. Sci. 2011, 7 
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mune diseases [15, 16].  In contrast, mice overex-
pressing human latent TGF-β1 are protected against 
progressive renal inflammation and fibrosis in ob-
structive and immunologically-induced crescentic 
glomerulonephritis [17-19]. These findings suggest a 
vital role for TGF-β1 in anti-inflammation. However, 
signaling mechanisms by which TGF-β1 exerts its 
anti-inflammatory properties remain unclear, alt-
hough TGF-β-induced inhibition of NF-κB-mediated 
renal inflammation via induction of 
Smad7-dependent IκBα expression has been recently 
considered [17, 19].  
Distinct role of active and latent TGF-β1 in 
renal fibrosis and inflammation 
While it is well understood that active TGF-β1 
acts as a critical fibrogenic growth factor mediating 
progressive renal fibrosis [11, 12], our recent studies 
showed that mice overexpressing latent TGF-β1 in the 
skin are protected against progressive renal inflam-
mation and fibrosis in obstructive and immunologi-
cally-induced crescentic glomerulonephritis [17-19]. 
This is associated with an up-regulation of endoge-
nous renal Smad7, an inhibitory Smad [17-19]. These 
remarkable findings are completely opposite to the 
findings from the previous reports that mice overex-
pressing the active TGF-β1 in the liver result in pro-
gressive liver and renal fibrosis [11, 12]. Thus, upreg-
ulation of renal Smad7 may be an important mecha-
nism through which latent TGF-β1 protects kidney 
from inflammation and fibrosis. This may be associ-
ated with prevention of renal Smad7 from 
Smurf-mediated ubiquitination and degradation in 
response to higher levels of latent TGF-β1. It may be 
also true that latent TGF-β1 may bind its own recep-
tor, GARP, to exert its anti-inflammatory effects via 
induction of Smad7 or Foxp3-dependent regulatory 
mechanisms [20, 21].  However, mechanisms under-
lying the distinct role of active versus latent TGF-β1 in 
renal fibrosis and inflammation remain largely un-
known. In addition, mechanisms whereby Smad7 is 
upregulated by latent TGF-β1, but degraded by the 
active form of TGF-β1 are also to be determined. 
Nevertheless, results from these studies implicate the 
complexity of TGF-β1 in the pathogenesis of kidney 
disease and the necessity to understand the diverse 
roles and mechanisms of active versus latent 
TGF-β1under disease conditions.  
TGF-β-dependent and independent Smad 
signaling in renal fibrosis 
Increasing evidence shows that in chronic kid-
ney diseases, TGF-β is not a sole molecule to activate 
Smads [3, 22]. Many mediators can activate Smad2 
and Smad3 independent from TGF-β1 because Smads 
act as signal integrators and interact with other sig-
naling pathways such as the mitogen-activated pro-
tein kinase (MAPK) signaling pathway and play a role 
in the pathophysiological processes of kidney diseases 
[3, 22]. As shown in Figure 1, under the diabetic con-
ditions, advanced glycation end-products (AGEs), an 
critical mediator in diabetic complications, are able to 
activate Smad2 and  Smad3 independently from 
TGF-β1 via the ERK/p38 MAP kinase-dependent 
mechanism [23, 24]. This is supported by the findings 
that deletion of TGF-β1 or TGF-β receptor II is unable 
to prevent AGE-induced Smad2 and Smad3 from ac-
tivation and fibrosis response [24]. In contrast, 
blockade of the engagement of AGE to its receptor 
(RAGE) with the soluble RAGE or ERK/p38 MAP 
kinases with the specific inhibitors or dominant nega-
tive ERK1/2 or p38 is able to prevent AGE-induced 
Smad2/3 phosphorylation and nuclear translocation 
[23, 24]. Similarly, under the hypertensive conditions, 
Ang II can activate the Smad signaling pathway to 
stimulate ECM production via the AT1 recep-
tor-mediated, ERK/p38 MAP kinase-Smad cross talk 
pathway (Figure 1),  in addition to the 
TGF-β-dependent mechanism [25, 26]. The important 
role for the MAPK-Smad crosstalk pathway in renal 
fibrosis is further demonstrated by the ability of Ang 
II and AGE to activate Smad2/3 to stimulate connec-
tive tissue growth factor (CTGF) expression in kidney 
cells lacking TGF-β1 gene or TβRII, but not in those 
with blockade of MAPK signaling by overexpressing 
dominant negative ERK1/2 and p38 or pre-treating 
cells with their specific inhibitors [24, 26]. All these 
studies reveal that activation of Smads under disease 
conditions is complicated and that targeting the 
TGF-β signaling at the receptor levels may not be an 
optimal therapeutic approach due to the existing in-
tracellular crosstalk pathways.  
It should be pointed out that within the TGF-β 
super family, TGF-β/Smads also interact with the 
BMP/Smads to counter-regulate each other to main-
tain the balance between two pathways in the path-
ophysiological process. It is well known that Smad1, 
Smad5 and Smad8 transduce BMP action, whereas 
Smad2 and Smad3 mediate TGF-β1 activities and the 
interactions between these two pathways can be at 
multiple levels including receptors and individual 
Smads [27]. It has been reported that TGF-β-activated 
Smad2/3 to mediate epithelial-mesenchymal transi-
tion (EMT) is reversed by addition of human recom-
binant BPM-7 via the Smad1-depdnent mechanism 
[28]. However, a subsequent study fails to show this Int. J. Biol. Sci. 2011, 7 
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counter-regulating activity [29], suggesting the com-
plexity between the TGF-β/Smad and BMP/Smad 
pathways under disease conditions.  
Diverse roles of Smad2 and Smad3 in ex-
tracellular matrix synthesis, EMT, and an-
giogenesis in kidney disease 
It is now well accepted that Smad2 and Smad3 
are two critical downstream mediators responsible for 
the biological effects of TGF-β1. In the context of renal 
fibrosis, Smad2 and Smad3 are strongly activated in 
both experimental and human kidney diseases, in-
cluding diabetic nephropathy [23, 24, 30-32], obstruc-
tive kidney diseases [18, 33-36], remnant kidney dis-
ease [37, 38], hypertensive nephropathy [25], 
drug-associated nephropathy [39], and immunologi-
cally-mediated glomerulonephritis [19, 40].  Many 
fibrogenic genes, such as (ColIa1, ColIa2, ColIIIa1, 
ColVa2, ColVIa1, and ColVIa3) and tissue inhibitor of 
MMP-1 (TIMP-1), are the downstream targets of 
TGF-β/Smad3 signaling [41], suggesting that Smad3 
may be a critical mediator of TGF-β/Smad signaling 
in fibrosis. An essential role for Smad3 in fibrogenesis 
is confirmed by the findings that deletion of Smad3 
from mice  suppresses fibrogenesis in a number of 
rodent models, including diabetic nephropathy [30], 
obstructive nephropathy [33], and drug toxici-
ty-related nephropathy [39]. Furthermore, the use of a 
Smad3 inhibitor to inhibit endothelial-myofibroblast 
transition and renal fibrosis in a type-1 diabetic kid-
ney disease demonstrates a therapeutic potential for 
kidney disease by targeting Smad3 signaling [42].  
While it is clear that TGF-β1 acts by stimulating 
Smad3 to mediate renal fibrosis, role of Smad2 in the 
kidney disease remains largely unknown. This is 
largely due to the unavailability of Smad2 knockout 
(KO) mice because of the embryonic lethality [43]. To 
explore the role of Smad2 in renal fibrosis, we gener-
ated conditional Smad2 KO mice by crossing the 
Smad2 floxed mouse with kidney specific promoter 
(Cadherin 16)-driven Cre transgenic mouse [44], 
which results in a conditional deletion of Smad2 from 
kidney TECs [45]. Unexpectedly, we found that spe-
cific deletion of Smad2 from the kidney significantly 
enhances renal fibrosis in a mouse model of UUO [45]. 
This is associated with enhanced Smad3 signaling. 
The in vivo finding is also confirmed in vitro in mouse 
embryonic fibroblasts (MEF) in which MEFs lacking 
Smad2 substantially enhance TGF-induced Smad3 
signaling including phosphorylation, nuclear trans-
location, Smad3 promoter activities, the binding of 
Smad3 to the collagen I promoter (COL1A2), and 
collagen matrix production [45]. Thus, although it is 
commonly believed that Smad2 and Smad3 bind to-
gether physically and work in a nonredundant man-
ner in embryonic development, Smad2 may function 
to competitively inhibit the phosphorylation of Smad3 
in response to TGF-β1 (Figure 2). It is also possible 
that the physical interaction of Smad2 and Smad3, 
together with Smad4, may affect phospho-Smad3 nu-
clear translocation and the subsequent binding to its 
target genes (Figure 2). Thus, loss of Smad2 enhances 
Smad3 signaling, thereby promoting Smad3-mediated 
collagen matrix expression in response to TGF-β1 and 
other fibrotic mediators including angiotensin II, 
AGE, and drugs [24-26, 37, 39]. 
 
 
 
 
 
Figure 2. Protective role of Smad2 in renal fibrosis. 
Smad2 physically binds Smad3 but prevents Smad3 from 
activation through two possible mechanisms: 1) competi-
tively inhibit Smad3 binding to the TβRI for phosphoryla-
tion; 2) block phosphorylated Smad3 nuclear translocation 
and binding to the DNA sequences, therefore inhibiting 
Smad3-mediated renal fibrosis. Blue lines (symbols) indicate 
protective or negative regulation pathways, while red ar-
rows (symbols) represent pathogenic or positive regulation 
pathways.  
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Epithelial-mesenchymal transition (EMT) has 
been long considered as a process leading to renal 
fibrosis [9]. Many studies have demonstrated that 
Smad3 plays a critical role in the EMT process in the 
kidney as well as in other disease conditions [37, 39, 
46-50].  To dissect the functional role of Smad2 and 
Smad3 in EMT, we conditionally knocked down 
Smad2 or Smad3 from renal tubular epithelial cells. 
Interestingly, disruption of Smad3, but not Smad2, 
attenuates Ang II-induced EMT as identified by a loss 
of an epithelial marker E-cadherin and a gain of 
mesenchymal phenotype α-SMA [37]. Similarly, 
knockdown of Smad3, but not Smad2, also blocks 
AGE and angiotensin II-induced CTGF expression 
and renal fibrosis [24, 26]. It is now well known that 
many fibrogenic genes (collagens) and EMT markers 
(α-SMA and E-cadherin) are Smad3-dependent [41, 
51, 52] and Smad3, but not Smad2, directly binding to 
the DNA sequences to regulate these target genes [52, 
53]. Thus, findings that knockdown of Smad3, but not 
Smad2, blocks CTGF expression and EMT provide a 
new evidence for an essential role of Smad3 in the 
EMT process.  
TGF-β1 has been known as a key mediator in 
controlling angiogenesis. Indeed, impaired angio-
genesis leads to the progressive renal fibrosis [54], 
whereas excessive angiogenesis has been associated 
with diabetic nephropathy [55]. It is now understood 
that TGF-β activates Smad2 and Smad3 to control the 
process of angiogenesis by diversely regulating ex-
pression of vascular endothelial growth factor 
(VEGF), a proangiogenic factor, and thrombospon-
din-1 (TSP-1), an antiangiogenic factor [56]. By using 
of Smad2 and Smad3 knockout mouse embryonic 
fibroblasts, TGF-β1-induced VEGF mRNA and pro-
tein expression in both Smad2 and Smad3 wild-type 
cells is blocked in cells null for Smad3, but not in 
Smad2. Whereas Smad2, but not Smad3, is critical for 
TSP-1 expression, demonstrating a critical role for 
Smad3 in angiogenesis while Smad2 as antiangiogenic 
factor in response to TGF-β1 [56]. Consistent with the 
antiangiogenic role of Smad2, we also demonstrated 
that Smad2, but not Smad3, mediated the expression 
of VEGF-A antagonist, a soluble VEGF-A receptor 
sFlt-1, in response to TGF-beta1 [56]. Thus, Smad2 and 
Smad3 have distinct roles in mediating the expression 
of pro- and antiangiogenic growth factors in response 
to TGF-β1.  
Diverse roles of Smad4 in renal fibrosis 
and inflammation  
It is now well accepted that TGF-β1 mediates fi-
brosis by causing the phosphorylation of Smad2 and 
Smad3, which forms a complex with the common 
Smad4 and then translocates to nuclei to bind and 
regulate the target genes [57]. Although Smad4 has 
been known as the common Smad in the signal 
transduction pathway of the TGF-β family, its func-
tional role in TGF-β1-regulated fibrosis and inflam-
matory responses remains largely unclear. This may 
be largely attributed to the lethality of Smad4 KO 
mice [58]. Recently, we generated conditional Smad4 
KO mice by crossing the Smad4 floxed mouse to the 
kidney specific promoter-driven Cre transgenic 
mouse in which Smad4 is deleted from most tubular 
epithelial cells upon Cre recombination [59]. We 
found that disruption of Smad4 from the kidney en-
hanced renal inflammation as evidenced by a greater 
CD45+ leukocyte and F4/80+ macrophage infiltration 
and up-regulation of IL-1β,  TNF-α,  MCP-1, and 
ICAM-1 in the obstructed kidney and in 
IL-1β-stimulated macrophages [59]. Further studies 
showed that the loss of Smad4 repressed Smad7 
transcription, therefore leading to a loss of Smad7 
functional  protein.  This,  in  turn,  inhibited  IκBα  ex-
pression but enhanced NF-κB  activation,  thereby 
promoting renal inflammation. In contrast, deletion of 
Smad4 inhibited progressive renal fibrosis such as 
collagen matrix expression in the obstructive 
nephropathy and TGF-β1-induced collagen I expres-
sion by fibroblasts [59]. Interestingly, the mechanism 
of deletion of Smad4 to suppress renal fibrosis is not 
associated with inhibition of Smad2/3 activation be-
cause disruption of Smad4 does not alter phosphory-
lation levels of Smad2/3 nor phosphorylated 
Smad2/3 nuclear translocation. This is consistent with 
the previous finding in Smad4 null cancer cell lines 
[60].  However, deletion of Smad4 influences 
Smad3-mediated promoter activities and the binding 
of Smad3 to the COL1A2 promoter [59]. It has been 
reported that Smad3 binding sequences are located in 
the promoter regions of COL1A2, COL2A1, COL3A1, 
COL5A1, COL6A1, and COL6A3 [61-63], therefore, 
disruption of Smad4 may influence the binding activ-
ity of Smad3 to the collagen promoter, thereby inhib-
iting the fibrotic response.  
Moreover, we also found that deletion of Smad4 
impairs Smad7 transcriptional regulation in inhibition 
of NF-κB signaling [59]. It has been shown that Smad7 
transcription is regulated by TGF-β1 through the di-
rect binding of Smad3 and Smad4 to the Smad7 pro-
moter [64, 65]. Thus, disrupted Smad4 results in a loss 
of Smad7 expression transcriptionally and impairs 
Smad7 promoter activities functionally [59]. Because 
Smad7 is capable of inducing IκBα  expression, an 
inhibitor of NF-κB [17], disruption of Smad4 reduces 
renal Smad7, thereby promoting NF-κB-dependent Int. J. Biol. Sci. 2011, 7 
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renal inflammation and the inhibitory effect of 
TGF-β1 on interleukin-1β-induced  inflammatory re-
sponse in macrophages in vivo and in vitro [59]. 
Taken together, Smad4 may be a key regulator for the 
diverse roles of TGF-β1 in inflammation and fibro-
genesis by interacting with Smad7 and Smad3 to in-
fluence their transcriptional activities in renal in-
flammation and fibrosis. (Figure 3). 
 
 
Figure 3. Diverse roles of Smad4 in renal fibrosis and inflammation. Smad4 binds phosphorylated Smad2/Smad3 to 
form the Smad complex that translocates into the nucleus to regulate target genes related to fibrogenesis including Smad7. 
Upregulation of Smad7 prevents NF-κB/p50/p65 from phosphorylation and nuclear translocation by inducing IκBα ex-
pression. Therefore, Smad4 acts as a fine turner to promote Smad3-mediated fibrosis while inhibiting NF-κB-driven in-
flammation. Blue lines (symbols) indicate protective or negative regulation pathways, while red arrows (symbols) represent 
pathogenic or positive regulation pathways.  
 
Inhibitory role of Smad7 in renal fibrosis 
and inflammation 
Smad7 is an inhibitory Smad and negatively 
regulates Smad2 and Smad3 activation by its negative 
feed-back mechanism.  Expression of Smad7 is in-
duced by TGF-β1, which, in turn, exerts its negative 
feedback mechanism by causing degradation of TβRI 
and Smads [7, 8, 66, 67]. In chronic kidney diseases, 
TGF-β1 and angiotensin II are able to induce Smad7 
mRNA expression and also activate the Smurfs and 
arkadia-dependent ubiquitin–proteasome pathways 
that, in turn, degrade Smad7 protein via a 
post-transcriptional modification mechanism [7, 8, 37, 
68, 69]. Smurf1, Smurf2, and arkadia are E3 ubiquitin 
ligases for Smad7 [7, 8, 68] and have been shown to 
physically interact with Smad7 [69, 70]. As shown in 
Figure 4, Smad7 acts as an adaptor protein to recruit 
E3 ubiquitin ligases such as Smurf2 and arkadia to the 
TGF-β receptor complex to promote its degradation 
through proteasomal-ubiquitin degradation path-
ways [7, 8, 68-70]. Once Smad7 is degraded, activation 
of Smad2/3 and renal fibrosis is enhanced. This is 
clearly demonstrated by the recent finding that Int. J. Biol. Sci. 2011, 7 
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up-regulation of renal Smurf2 causes an ubiqui-
tin-dependent degradation of renal Smad7, resulting 
in enhanced TGF-β/Smad signaling and progressive 
renal fibrosis [69]. Furthermore, Smurf2 can interact 
with Smad2 and selectively target Smad2 and Smad 
transcriptional corepressors Ski, SnoN, and 
TG-interacting factor (TGIF) for degradation in tubu-
lar epithelial cells, leading to progressive renal fibro-
sis and EMT in a mouse model of obstructive kidney 
disease [71-73]. Thus, ubiquitin-mediated degradation 
of Smad7 and Smad transcriptional corepressors Ski, 
SnoN, and TGIF promotes further activation of TGF-β 
signaling and progressive renal fibrosis as evidenced 
in a number of animal models [36, 37, 69, 72, 73]. This 
is further supported by the findings that Smad7 KO 
mice develop more severe renal fibrosis in both ob-
structive nephropathy and diabetic kidney disease [32, 
36].  
Loss of renal Smad7 not only  enhances 
TGF-β/Smad3-mediated renal fibrosis, but also en-
hances renal inflammation by activating the 
NF-κB-dependent inflammatory pathway [17, 32, 36, 
40]. It is well recognized that activation of NF-κB/p65 
is associated with the renal inflammation in crescentic 
glomerulonephritis,  diabetic nephropathy, and ob-
structive nephropathy [17, 32, 36, 40]. Overexpression 
of Smad7 substantially inhibits DNA binding activity, 
nuclear translocation, transcriptional activity of 
NF-κB/p65, as wells as NF-κB-dependent inflamma-
tory responses induced by IL-1β and TNFα [17], im-
plying a functional link between the Smad7 and 
NF-кB. As shown in Figure 4, Smad7 is able to induce 
IκBα  expression, an inhibitor of NF-κB, suggesting 
that TGF-β may act by stimulating Smad7 to induce 
IκBα expression to suppress NF-κB activation [17].  
 
 
Figure 4. Inhibitory role of Smad7 in renal fibrosis and inflammation. Overexpression of Smad7 prevents Smad2/3 
from phosphorylation by degrading the TβRI as well as Smads via the ubiquitin degradation pathway (Ub), thereby inhibiting 
Smad3-dependent renal fibrosis in response to TGF-β1, AGEs, and angiotensin II (Ang II). In addition, overexpression of 
Smad7 can induce IκBα, an inhibitor of KF-κB, therefore inhibiting NF-κB-driven renal inflammation. Thus, Smad7 acts as a 
therapeutic agent for treatment of kidney diseases. Blue lines (symbols) indicate protective or negative regulation pathways, 
while red arrows (symbols) represent pathogenic or positive regulation pathways. Int. J. Biol. Sci. 2011, 7 
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The ability of overexpression of renal Smad7 to 
inhibit NF-κB activation and renal inflammation in 
remnant kidney disease [74], autoimmune crescentic 
glomerulonephritis [40], and diabetic nephropathy [32] 
confirms the potential role of Smad7-NF-κB crosstalk 
pathway in renal inflammation. Evidence for the an-
ti-inflammatory role of Smad7 also comes from the 
findings that Smad7 KO mice develop more severe 
kidney inflammation in diabetic kidney disease and 
UUO models because these  mice have significantly 
higher phosphorylation levels of NF-κB/p65 along 
with higher levels of renal inflammation including 
upregulation of IL-1β,  TNFα,  MCP-1, ICAM-1, and 
the development of more macrophage infiltration 
whine the kidney when compared to wild-type mice 
[32, 36]. In contrast, mice that transgenically express 
Smad7 on T cells are protected against crescentic 
glomerulonephritis [75].  Therefore, inhibition of the 
NF-κB signaling pathway  by inducing IκBα expres-
sion may be the major mechanism by which Smad 7 
inhibits renal inflammation (Figure 4). 
The therapeutic potential for Smad7 on renal in-
flammation and fibrosis have been examined in  rat 
models of obstructive nephropathy [34, 35], remnant 
kidney disease [38, 74], diabetic nephropathy [32], and 
in a mouse model of autoimmune crescentic glomer-
ulonephritis [40]. In these studies, Smad7 was trans-
ferred into the kidney using the ultra-
sound-microbubble-mediated gene therapy tech-
nique. Overexpression of Smad7 not only inhibits 
Smad3-mediated renal fibrosis such as collagen ma-
trix expression including epithelial-mesenchymal 
transition, but also blocks NF-κB-driven renal in-
flammation including accumulation of macrophages 
and T cells in both glomeruli and tubulointerstitium 
and upregulation of renal IL-1, TNFα, ICAM-1, and 
iNOS. Thus, restored the renal Smad7 rebalances the 
TGF-β/Smad and NF-κB signaling pathways and, 
therefore, inhibits progressive renal functional injury 
(Figure 4). All these studies demonstrate that Smad7 
not only plays a negatively regulating role in renal 
fibrosis and inflammation, but also acts as a thera-
peutic agent and has therapeutic effect on renal fibro-
sis and inflammation [76]. 
Regulation of TGF-β/Smad3-dependent 
microRNAs in renal fibrosis 
Recent studies in microRNAs have demonstrat-
ed that TGF-β regulates specific microRNAs to influ-
ence renal fibrosis in kidney diseases. Recent reports 
from our laboratory and others describe several mi-
croRNAs to be regulated by TGF-β1 during kidney 
diseases as detailed in a recent review article [77]. 
Indeed, TGF-β1 is able to up-regulate miR-21, miR-93, 
miR-192, miR-216a, miR-377, but down-regulates the 
miR-29 and miR-200 families [77]. We have recently 
identified that, among these TGF-β-dependent miR-
NAs, miR-21, miR-192, and the miR-29 family ex-
pression during renal fibrosis is tightly regulated by 
TGF-β1 via the Smad3, but not Smad2, dependent 
mechanism [78-80], which is also illustrated in Figure 
5. Indeed, in vitro studies reveal that deletion of 
Smad3, not Smad2, inhibits expression of miR-21 and 
miR-192, but enhances the miR-29 family expression 
in response to TGF-β1 in both mouse embryonic fi-
broblasts and kidney tubular epithelial cells [78-80]. 
Evidence supporting the interaction of Smad3 with 
miR-21, miR-192, and miR-29 also came from the 
findings that there are conserved Smad3-binding sites 
in the promoter region of all three miRNAs and that 
Smad3 is able to interact with their individual pro-
moter region as detected by the Chip assay [78-80]. 
Interestingly, expression of miRNAs can also interact 
with Smad3 to influence the Smad3 activity and func-
tions. It is reported that overexpression of miR-200a 
could decrease Smad3 activity and attenuate 
TGF-β1-induced fibrosis [81]. However, although it 
remains undetermined if this interaction is direct or 
indirect, such an observation indicates the complexity 
between TGF-β/Smads and miRNAs under patho-
physiological conditions.  
The regulating role of TGF-β/Smad3 in expres-
sion of miRNAs during renal fibrosis is also detected 
in an experimental mouse model of obstructive 
nephropathy by miRNA microarray and real-time 
PCR. Mice null for Smad3 are protected against renal 
fibrosis along with the inhibition of miR-21 and 
miR-192 expression [78, 79]. In contrast, while severe 
renal fibrosis in the obstructive nephropathy in 
Smad3 wild-type mice  is associated with a loss of 
miR-29, prevention of renal fibrosis in Smad3 knock-
out mice is largely attributed to an increase in expres-
sion of renal miR-29 [80].  
Smad7 also plays a role in regulating 
Smad-dependent  miRNA expression in response to 
TGF-β1. For example, In vitro, overexpression of 
Smad7 in tubular epithelial cells abolished 
TGF-β1-induced miR-192 expression [78]. In vivo, 
deletion of Smad7 enhanced Smad3 signaling, thereby 
promoting miR-192 expression and fibrosis in ob-
structive kidney disease. In contrast, overexpression 
of Smad7 blocks TGF-β/Smad signaling and thus 
inhibits miR-192 expression and renal fibrosis in the 
rat 5/6 nephrectomy model. Int. J. Biol. Sci. 2011, 7 
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Figure 5.  Smad3-dependent miRNAs in renal fi-
brosis. TGF-β1 acts by stimulating Smad3 to positively 
regulate miR-21 and miR-192, but negatively regulate the 
miR-29 or miR-200 families, to mediate renal fibrosis. Blue 
lines (symbols) indicate protective or negative regulation 
pathways, while red arrows (symbols) represent pathogenic 
or positive regulation pathways. 
 
The important role of TGF-β/Smad3-dependent 
miRNAs in renal fibrosis is demonstrated by the in 
vitro findings that overexpression of miR-21 and 
miR-192 enhances, but knockdown of miR-21 or 
miR-192 inhibits, collagen matrix expression in re-
sponse to TGF-β1 [78, 79]. In contrast, knockdown of 
miR-29 enhances fibrosis, whereas overexpression of 
miR-29 blocks collagen I expression in response to 
TGF-β1 [80].  
More excitingly, we recently demonstrated that 
the  ultrasound-microbubble-mediated gene transfer 
technique can also be used to deliver the miRNAs into 
the kidney and have proved that the ultra-
sound-mediated miRNA therapy is a novel and effec-
tive therapeutic approach for kidney disease. Indeed, 
ultrasound-mediated overexpression of miR-29b or 
knockdown of miR-21before or after the established 
mouse model of obstructive nephropathy is capable of 
preventing or halting the progression of renal fibrosis 
[79, 80]. These findings suggest that specific targeting 
the Smad3-dependent microRNAs related to fibro-
genesis such as miR-21 and miR-29 may represent a 
novel and specific anti-fibrosis therapy for renal fi-
brosis.  
Concluding Remarks 
The current advances in research into the 
TGF-β/Smad signaling pathway improve our under-
standing of the molecular mechanisms of renal fibro-
sis and inflammation in chronic kidney diseases. In 
general, Smad3 is a downstream key mediator of 
TGF-β/Smad signaling and plays a pathogenic role in 
both renal inflammation and fibrosis (Figure  1). 
Smad3 may also positively or negatively regulate its 
downstream specific miRNAs such as miR-21, 
mir-192, and miR-29 to mediate renal fibrosis (Figure 
5). In contrast, Smad2 is renoprotective and sup-
presses renal fibrosis by competitively inhibiting 
Smad3 signaling including phosphorylation and nu-
clear translocation (Figure 2). Smad4 is the common 
Smad and plays a diverse role in promoting 
Smad3-mediated renal fibrosis but suppressing 
NF-κB-driven renal inflammation by stimulating 
Smad7 expression transcriptionally (Figure 3). Most 
importantly, Smad7 is a negative regulator of both 
renal inflammation and fibrosis. Smad7 inhibits 
TGF-β/Smad signaling by recruiting the E3 ligases 
such as Smurf2  and arkadia  to the TGF-β  receptor 
complex or Smads  to promote their degradation 
through the proteasomal-ubiquitin degradation 
pathway. In addition, Smad7 can induce IκBα  ex-
pression, thereby preventing NF-κB subunits from 
phosphorylation. However, Smad7 is lost in the dis-
eased kidney, which causes an imbalance within and 
between the TGF-β/Smad and NF-κB signaling 
pathways, resulting in the development of renal fi-
brosis and inflammation. Therefore, restored renal 
Smad7 rebalances both Smad and NF-κB signaling 
pathways and inhibits renal fibrosis and inflamma-
tion (Figure 4). Thus, understanding  of  the specific 
role of individual Smads and the crosstalk pathways 
is the first step towards the development of novel and 
effective therapeutic strategies for kidney diseases.  
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